Sigma-Aldrich Joins Phase 2 of The RNAi Consortium to Validate shRNA... (RNAi reagents guaranteedto work out of t...)

Sigma-Aldrich Joins Phase 2 of The RNAi Consortium to Validate shRNA Libraries

Date:5/7/2008

RNAi reagents guaranteed to work out of the box. Sigma-Aldrich will also expand its program to promote and educate the research community about the multiple applications of RNAi technology by providing educational tools and forums.

"Sigma-Aldrich is committed to the development of RNAi technology. Through our collaboration with TRC2, we're producing the most highly validated shRNA libraries available to the research community," said Dave Smoller, President of Sigma-Aldrich's Research Biotech Business Unit. "By making these tools available to researchers worldwide, Sigma-Aldrich is facilitating advanced disease and drug discovery research."

Lentiviral-based shRNA libraries enable researchers to study gene function and disease, both in standard cell lines and recognized difficult cell types such as primary, non-dividing, growth-arrested or terminally differentiated cells. Such cell lines are typically not amenable to standard transfection or genomic integration by other viral delivery systems, but they may be transduced efficiently with lentiviral particles.

"Over the coming years, The RNAi Consortium intends to build upon its successes with shRNA to facilitate loss-of-function genetic screens in mammalian cells," said David Root, Director of the RNAi Platform at the Broad Institute of MIT and Harvard and project leader for TRC2. "The existing TRC library has already proven highly effective for systematic viral-delivery RNAi screening. TRC2 will generate significant further improvements to the library and its applications."

The current MISSION(R) shRNA clone libraries comprise a comprehensive collection of more than 160,000 pre-cloned lentiviral-based shRNA vector constructs targeting more than 16,000 human genes (MISSION TRC-Hs1.0) and 16,000 mouse genes (MISSION TRC-Mm1.0). For more information about the MISSION(R) shRNA clone collections, please visit us online at http://www.sigma.com/tr
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Sigma-Aldrich to Present at the Baird 2008 Growth Stock Conference on Tuesday, May 13, 2008
2. Sigma-Aldrich to Present at the Bank of America 2008 Healthcare Conference on Tuesday, May 13, 2008
3. Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands
4. Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%.
5. Sigma-Aldrich Corporation 1st Quarter 2008 Earnings Conference Call
6. Sigma-Aldrich Partners With Sunset Molecular Discovery to Expand Your Favorite Gene Search Tool
7. Sigma-Aldrich To Hold Annual Business Review
8. Sigma-Aldrich, Oxford BioMedica and Open Biosystems Settle Patent Dispute Over Use of LentiVector Technology in Research Reagents
9. Sigma-Aldrich and MorphoSys Enter Into a Collaboration and Licensing Agreement for Recombinant Research Antibodies
10. Sigma-Aldrich Names Helge Bastian New VP of Global Marketing for Research Biotech
11. Sigma-Aldrich Announces New Prestige Antibodies(TM) Line for Proteomics and Cell Biology Researchers

Post Your Comments:

Sigma-Aldrich Joins Phase 2 of The RNAi Consortium to Validate shRNA...(RNAi reagents guaranteedto work out of t...)